Riskpilot← Back to searchSign inGet full accessMolderm AB
ABActiveOrg 5592847049Dockplatsen 1 Vån 7Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20200 employees
Revenue 2024
SEK 0
EBITDA margin
—
-52% vs 2023
Equity ratio
21.4%
Financial strength
Net profit 2024
SEK -5K
-101% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | -52% |
| Net profit | SEK -5K | -101% |
| Total assets | SEK 542K | -1% |
| Equity | SEK 116K | -78% |
| Employees | 0 | — |
Legal name
Molderm AB
Org number
5592847049
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23 november 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla klinik-koncept internationellt inom estetiska behandlingar samt distribution av medicintekniska produkter internationellt samt därmed förenlig verksamhet.
Address
Dockplatsen 1 Vån 7
Email
markus@molderm.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −2 | −3 | −3 | −5 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | −2 | −3 | −3 | −5 |
| Net financials | — | −1 | 500 | −0 |
| Profit before tax | −2 | −4 | 502 | −5 |
| Tax | −0 | — | — | — |
| Net profit | −2 | −4 | 502 | −5 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 48 | 44 | 547 | 542 |
| Equity | 23 | 19 | 521 | 116 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 25 | 25 | 26 | 426 |
| Total debt | 25 | 25 | 26 | 426 |
EBITDA margin
-470800.0%
This company
15.8%
Market median
-2979847% vs market
20212024
Equity ratio
21.4%
This company
38.2%
Market median
-44% vs market
20212024
Return on equity
-4.1%
This company
18.4%
Market median
-122% vs market
20212024
Net profit margin
-472500.0%
This company
8.1%
Market median
-5833433% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
3.67×
This company
0.62×
Market median
-492% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Markus & Elias Family AB | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Markus & Elias Family AB
Molderm AB Board members of Molderm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Markus Nilsson | Chief Executive Officer | 0 companies |
| Emma Maria Persson | Deputy Board Member | 0 companies |
| Elias Assarsen | Chairman | 0 companies |